{"id":"pro-netupitant-palonosetron","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pro-netupitant works by blocking the action of substance P/neurokinin 1 (NK1) receptors, which are involved in nausea and vomiting. Palonosetron, on the other hand, blocks the action of 5-HT3 receptors, which are also involved in nausea and vomiting. By blocking these receptors, pro-netupitant/palonosetron combination helps to prevent nausea and vomiting caused by chemotherapy.","oneSentence":"Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:16.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"}]},"trialDetails":[{"nctId":"NCT03403712","phase":"PHASE3","title":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2018-03-16","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":404},{"nctId":"NCT02517021","phase":"PHASE3","title":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-11","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":405}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ANAPHYLACTIC SHOCK"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IV NEPA FDC"],"phase":"phase_3","status":"active","brandName":"Pro-netupitant/Palonosetron","genericName":"Pro-netupitant/Palonosetron","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pro-netupitant is a substance P/neurokinin 1 (NK1) receptor antagonist, while palonosetron is a 5-HT3 receptor antagonist. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}